Once merged, the new company will have 13 assets in clinical trials and 11 in phase II/III clinical trials as well as a robust early stage pipeline. The groups expect that the combination of NantKWest's natural killer (NK) cell platform and ImmunityBio's immunotherapy fusion protein, immunomodulator, and adenovirus platforms will result in more late stage NK cell and T cell-based candidates. Together, the new company will occupy over 20,000 sq ft of manufacturing and research and development facilitates.

Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the transaction, on a fully diluted basis, ImmunityBio shareholders will own approximately 72% of the combined company and NantKwest shareholders will own approximately 28% of the combined company. The transaction is expected to close in the second half of 2021. Following closing, the combined company will assume the ImmunityBio name (IBRX) and continue to be listed on the NASDAQ exchange.

Richard Adcock will become the CEO of the combined company, and Dr. Patrick Soon-Shiong (founder of ImmunityBio) will serve as executive chairman of the board. The combined company will be headquartered at ImmunityBio's offices in Culver City, California.

ImmunityBio COVID-19 oral vaccine effective in nonhuman primates
ImmunityBio's COVID-19 vaccine candidate has been shown to protect nasal and lung airways of nonhuman primates against SARS-CoV-2 in preclinical studies.

ImmunityBio touts preclinical data on NK cell therapy boosting product
ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin-15 "superagonist," improves interferon-gamma...

ImmunityBio COVID-19 vaccine shows positive clinical results
ImmunityBio has demonstrated that antigens from its bivalent adenovirus-based vaccine candidate are recognized by SARS-CoV-2 reactive human T cells in...

ImmunityBio, NantKwest launch COVID-19 vaccine trial
ImmunityBio and NantKwest have launched phase I of a clinical trial for a COVID-19 vaccine candidate.

ImmunityBio begins phase I trial for its COVID-19 vaccine candidate
ImmunityBio has been authorized by the U.S. Food and Drug Administration to begin a phase I clinical trial of its hAd5-COVID-19 vaccine candidate.

NantKwest scales up COVID-19 stem cell therapy
NantKwest announced that it received investigational new drug authorization from the U.S. Food and Drug Administration (FDA) to treat patients with acute...